Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)

NCT02564263 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

628

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Carcinoma
Esophagogastric Junction Carcinoma

Interventions

BIOLOGICAL: pembrolizumab
DRUG: paclitaxel
DRUG: docetaxel
DRUG: irinotecan

Sponsor

Merck Sharp & Dohme LLC